Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued to investors on Thursday, Marketbeat Ratings reports.
Several other research firms also recently commented on ENTA. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Royal Bank of Canada downgraded Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 target price on the stock. in a report on Tuesday, January 2nd. Finally, TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $51.25.
Enanta Pharmaceuticals (ENTA) traded down $1.24 during trading on Thursday, reaching $73.42. The company’s stock had a trading volume of 460,761 shares, compared to its average volume of 249,382. Enanta Pharmaceuticals has a twelve month low of $25.92 and a twelve month high of $95.91. The company has a market capitalization of $1,406.07, a P/E ratio of 42.44 and a beta of 1.04.
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Enanta Pharmaceuticals by 4.3% in the fourth quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock worth $137,521,000 after purchasing an additional 97,054 shares during the last quarter. First Manhattan Co. raised its stake in shares of Enanta Pharmaceuticals by 14.5% in the fourth quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock worth $63,620,000 after purchasing an additional 137,100 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Enanta Pharmaceuticals by 6.9% in the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock worth $30,475,000 after purchasing an additional 54,856 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Enanta Pharmaceuticals by 1.4% in the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after purchasing an additional 7,617 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Enanta Pharmaceuticals by 4.1% in the second quarter. Northern Trust Corp now owns 195,712 shares of the biotechnology company’s stock worth $7,041,000 after purchasing an additional 7,772 shares during the last quarter. Hedge funds and other institutional investors own 67.86% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/11/enanta-pharmaceuticals-enta-rating-lowered-to-neutral-at-jpmorgan-chase-co.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.